Composite Score Methods to Evaluate Part D Organization's Performance over multiple Measures For American Public Health Association (APHA) Annual Conference.

Slides:



Advertisements
Similar presentations
Optima Medicare (PPO) Plans CY Medicare Medicare is a Federal health insurance program for those age 65 or older or individuals at any age who have.
Advertisements

Making Payment Reforms Work for Patients and Families Lee Partridge Senior Health Policy Advisor National Partnership for Women and Families January 28,
CY2009 Medicare Plan Ratings: November 2008 Release for Open Enrollment Alice Lee-Martin, PharmD Liz Goldstein, Ph.D. Center for Drug and Health Plan Choice.
Credit Risk In A Model World
Cross Sectional Designs
Convenient Access to Retail Pharmacies - Analysis on Preferred Cost-Sharing Pharmacy Networks December 16 & 17, 2014 Division of Benefit Purchasing and.
(CAHPS) Experience of Care Surveys From Design to Implementation
Medication Therapy Management: Methods to Increase Comprehensive Medication Review Participation Harrell T, RPh, Diaz M, PharmD Candidate, Ortega Y, PharmD.
California Medicare Coalition Medicare and Part D: Who Regulates What? Federal and State Responsibilities The California Medicare Coalition is supported.
1 A Parsimonious Patient-Reported Measure of Care Coordination Ron D. Hays, Ph.D. UCLA Department of Medicine September 27, 2013 Los Angeles, CA
Welcome We’re glad you’re here!. Medicare Basics.
MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
Rankings: What do they matter, what do they measure? Anne McFarlane August 18, 2010.
Holding Health Plans & Providers Accountable for High-Quality, Patient-Centered Care January 23, 2015.
CMS 5 STARS PROGRAM MedPOINT Management.
Medicare Supplemental Insurance 101 A brief overview of Medicare Supplemental Insurance and how it works. Agentlink Senior Brokerage Created 4/14/2014.
Long Term Care: Medicare Prescription Drug Coverage in Institutions and Our Communities Larry Kocot Vanessa Duran.
Enrollment Guidance for Medicare Part D Plans Presented by America’s Health Insurance Plans (AHIP) and The National Association of Health Underwriters.
Medicare Prescription Drug Coverage. What’s Different About Prescription Drug Information? One size does not fit all, more than ever before Distinct messages.
Measuring Quality & Performance in Medicare Advantage Where We’ve Been, Where We Are, & Where We’re Going Abby L. Block Director, Center for Beneficiary.
Medicare Advantage Quality Measurement & Performance Assessment Training Conference April 8-9, 2008 Empowering a More Informed Consumer: Medicare Plan.
Factor Analysis Psy 524 Ainsworth.
HEDIS Overview and Update
Joint Informational Hearing The Federal Medicare Prescription Drug Act: State Readiness, Implementation, and Consumer Issues Bonnie Burns, Training and.
Psychometric Properties of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Group Adult Visit Survey September 11, 2012.
MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.
The Standardized Infection Ratio Steven P Hudson, MBA, MA Statistician Health Care Excel, Inc.
There’s So Much More to Medicare, Let’s Talk Humana Medicare Advantage Health and Prescription Drug Plans M0006_GH210S6RR KC0906.
INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.
Medicare: An Overview September 30, 2014 Society for Financial and Professional Development 7 th Annual Financial Literacy Leadership Conference Christina.
Medicare Advantage Plans and Other Medicare Plans Module 11.
The ABC&D’s of Medicare. What is Medicare? Medicare is health insurance for: People 65 or older People under 65 with certain disabilities People of any.
MMA Implementation: Employer Response to the MMA The Second National Medicare Prescription Drug Congress Mark Hamelburg, Director Employer Policy & Operations.
CMS CAHPS Surveys: Public Reporting
IOPS Toolkit for Risk-based Supervision Module 4: Risk Mitigation and Scoring.
Slide 1 Estimating Performance Below the National Level Applying Simulation Methods to TIMSS Fourth Annual IES Research Conference Dan Sherman, Ph.D. American.
STATE PERSPECTIVES ON IMPLEMENTATION OF MEDICARE PART D: COORDINATING MEDICARE AND MEDICAID COVERAGE THROUGH SPECIAL NEEDS PLANS James M. Verdier Mathematica.
Medicare and ACOs Models CEO Call January 12, 2012.
Quality Through the Eyes of the Patient: State-of-the-Art Concepts Paul D. Cleary, Ph.D. April 10, 2001 Quality Through the Eyes of the Patient: State-of-the-Art.
RANDRAND CAHPS® Relevance of CAHPS® for Workers’ Compensation Medical Care Donna Farley Senior Health Policy Analyst, RAND Workers’ Compensation Colloquium.
On visible choice set and scope sensitivity: - Dealing with the impact of study design on the scope sensitivity Improving the Practice of Benefit Transfer:
1 Variation in Medicare Part D Prescription Drug Plan Benefits, 2006 Leslie M. Greenwald, Ph.D. Principal Scientist RTI, International.
“The Effect of Patient Complexity on Treatment Outcomes for Patients Enrolled in an Integrated Depression Treatment Program- a Pilot Study” Ryan Miller,
Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.
1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute National Academy of Social Insurance.
Disparity Implications of the Eligibility Criteria for Medication Therapy Management Services among the Non-Medicare Population Junling Wang, Ph.D., Lawrence.
Rajul A. Patel, PharmD, PhD, Kate M. O'Dell, PharmD, Kenneth Wang, Pharm D Candidate, Shu Lu, Pharm D Candidate, Tiffany Chu, Pharm D Candidate, Kim-Anh.
Slide -1 Medicare Prescription Drug Coverage Atlanta Regional Office Centers for Medicare & Medicaid Services September 12, 2005.
Exhibit 1 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. Analysis includes non-LIS.
"Helping Seniors Make Smart Decisions about their Drug Coverage Options" Hal Prink, FHFMA, Medicare Patient Advocate, Senior’s Voice for Healthcare Rights.
Generalizing Observational Study Results Applying Propensity Score Methods to Complex Surveys Megan Schuler Eva DuGoff Elizabeth Stuart National Conference.
Applied Quantitative Analysis and Practices
Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
1. 2 Y e s 3 Y e s The initial enrollment period for people with Medicare and some Medicaid is the same as for other enrollees. If these individuals.
Medicare Open Enrollment For Coverage in 2016 Starts October 15, 2015 Ends December 7, MEDICARE Medicare.gov.
Pediatric Asthma Hospitalizations: Impact of Managed Care in the Patterns of Outpatient Healthcare Utilization Capriles, JA., Rodríguez, MH., Rios, R.,
CMS SAS Users Group Conference Learn more about THE POWER TO KNOW ® October 17, 2011 Medicare Payment Standardization Modeling using SAS Enterprise Miner.
Methods of multivariate analysis Ing. Jozef Palkovič, PhD.
Medicare Part C & D 2012 Plan Ratings SNP Leadership Forum October 28, 2011 Liz Goldstein, Ph.D. Centers for Medicare & Medicaid Services.
Managed Health Care Manar alramli
Why pricing transparency?
Areas for Discussion Description of plan ratings.
MEDInsights™.
2018 Medicare Prescription Drug Benefit
2019 Medicare Prescription Drug Benefit
MEDICAID AND MMA ADMINISTRATIVE CHALLENGES: SPECIAL NEEDS PLANS
Jan Berger, M.D., M.J. Senior Vice President Chief Medical Officer
Presentation transcript:

Composite Score Methods to Evaluate Part D Organization's Performance over multiple Measures For American Public Health Association (APHA) Annual Conference Philadelphia, Nov 10, 2009 Presenters: Ying Wang, PhD, IMPAQ International (IMPAQ); Sungsoo Oh, MS, Centers for Medicare & Medicaid Services (CMS) Co-authors: Arthur Kirsch, PhD, IMPAQ; Christopher Powers, PharmD, CMS; Oswaldo Urdapilleta, PhD, IMPAQ; and Vikki Oates, CMS SPONSOR: Centers for Medicare & Medicaid Services (CMS)

Presenter Disclosure Presenters: Ying Wang & Sungsoo Oh The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months: No relationships to disclose 2

Background Medicare Modernization Act (MMA) and Medicare Part D program (Since 2003) – Medicare Advantage plans that offer prescription drug benefits (MA-PD) – Stand-alone prescription drug plans (PDP) CMS roadmap in quality improvement – Value-based purchasing (VBP) – Quality and performance measurement – Transparency and consumer choice empowerment 3

Project Objective Report card system: Use star ratings to evaluate Part D organization’s performance – along with the rating system for other health care providers (e.g. hospitals, nursing homes, etc.) – Individual measure star – Domain level star: Group related measures into domains – Summary score: Summarize all measure stars into a single rating Use grouping methodology to collapse individual performance measures into domains, and use domain and summary score to rank health plans, and to reduce the level of information beneficiaries need to absorb 4

Data CMS Part D performance measures for 2009 open enrollment which started in Nov, 2008 – therefore, this analysis is using 2008’s data. 545 Part D contracts (462 MA-PD; 83 PDP) Primary data sources for measures: – Call center operation data – Complaints Tracking Module (CTM) – Consumer Assessment of Healthcare Providers and Systems (CAHPS) – Data forwarded by Independent Review Entity (IRE) – Management Information Integrated Repository (MIIR) – Medicare Beneficiary Database (MBD) – Medicare Advantage Prescription Drug System (MARx) 5

Data – Performance Measures Based on CMS’s grouping structure used for 2009’s open enrollment (Started from Nov, 2008): Drug Plan Customer Service  Time on Hold When Customer Calls Drug Plan  Calls Disconnected When Customer Calls Drug Plan  Time on Hold When Pharmacist Calls Drug Plan  Calls Disconnected When Pharmacist Calls Drug Plan  Complaints about the Drug Plan  How Helpful Is Your Plan When You Need Information  Rating of Drug Plan Using Your Plan to Get Your Prescriptions Filled  Rating of Drug Plan  Pharmacists Have Up-to-date Information on Plan Members Who Need Extra Help  Complaints about the Plan’s Benefits and Access to Prescription Drugs  Complaints about Joining and Leaving the Plan  Delays in Appeals Decisions  Reviewing Appeals Decisions Drug Pricing Information  Availability of Drug Coverage and Cost Information  How Often the Plan’s Drug Prices Change  Complaints about the Plan’s Drug Pricing and Out-of-pocket Costs 6

Grouping Methods Literature review of the prospective grouping methods – exploratory factor analysis (EFA) – confirmatory factor analysis (CFA) – principal component analysis (PCA) – cluster analysis – common/principal factor analysis (PFA) Strength and Limitations of each method Identified PFA and cluster analysis passed initial screening and were chosen for actual data analyses 7

Analysis Guidelines from CMS Missing data should not be imputed because of the lack of correlation among contracts, but approaches to deal with missing data should be explored. The same grouping structure should be applied to both MA-PD and PDP. Unsuppressed data and raw scores should be utilized to test the groupings. Since several variables are rates based on a denominator of enrollment with an exclusion rule of 800, some analyses is based only on contracts with 800 or more enrollees. For measures that are not loaded into factors, CMS reserves the right to assign them to groups subjectively. Three groups would be preferred as it is consistent with the previous year’s domain number. 8

Data Problems and Remedies Problems – Large missing data with CAHPS (50%~) – Measures with skewed distribution – Correlation between some measures are too high Remedies – Treated CAHPS measures separately – Log-transformed some measures that are skewed – Dropped one measure if highly correlated w/ the other – Sensitivity analysis, i.e.- tested the different choices of analytical datasets and analysis methods 9

Other Decision Points in Analysis Principal Factor Analysis (PFA) – Selection of the factor model – Selection of the factor rotation technique – Choice of the factor significance level – Determination of the number of factors to retain Cluster Analysis – Choice of clustering methods – Determination of the optimal number of clusters PFA as the primary grouping method, and Cluster Analysis as the validation tool 10

Findings – PFA results 11

Findings – Cluster Analysis Cluster analyses were performed on the similar datasets used for PFA. Similar results (grouping structure) were observed by cluster analysis, which verified the PFA results. 12

Conclusions Although some measures seem to be difference between MA- PD and PDP contracts, based on simple t tests among two groups, the analyses by either the combined data or MA-PD alone generated similar results in both the principal factor analysis and the cluster analysis. Among the three groups derived, one group (factor 3) is not stable and the internal consistency reliability is relatively low. Dropping the fuzz value and relaxing the number of groups parameter does not improve the factor loadings. The small number of contracts did challenge the stability and significance level of factor loadings. 13

Conclusions (Continued) The large amount of missing data associated with the CAHPS measures creates a real analytical problem if they are combined with the other measures in analysis. Several measures were not loaded into any of the three primary factors, even after several adjustments were made to the model. Although these measures ended up loading into different groups in various sensitivity analyses, the internal consistency reliability was significantly jeopardized. In setting the number of groups to 3, both the factor analysis and cluster analysis generated very similar results as well. 14

Conclusions (Continued) CAHPS measures should be reported separately from the groupings of the other variables. For measures not loaded into any groups, CMS is interested in subjectively assigning them to certain group/domain by priori. Naming of the factors is largely driven by the measure(s) that have higher loadings in their respective groups. The statistical analysis does not load all measures into groups, but to make the best use of all performance measures, a policy decision will be necessary to assign measures appropriately to the final grouping structure, based on subject matter expertise. 15

Conclusions (Continued) 16 Some new performance measures were later added and older measures retired during the method development process. The final grouping structure chosen for 2009 open enrollment and public reporting is below:

Next Step Use more recent performance data to re-run the analysis and further test the grouping structure Merge in more data at different time points to create a longitudinal data to test the robustness of the data-driven grouping structure 17

Thank you! Additional questions/comments, see us afterwards … 18